ADCT
NYSE
$1.27
Adc Therapeutics SA (ADCT)
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Sector:
Healthcare
Buy
Target: $5 (+295.26%)
Market Cap
$163M
Free Cash Flow Yield
-70.39%
Beta (5Y)
1.47
Price Chart
Valuation
Market Cap$163M
P/S2.06
P/B3.42
Profitability
Total Revenue (TTM)$84M
Gross Profit (TTM)-$21M
EBITDA-$113M
Profit Margin-173%
Operating Margin-121.1%
EPS-$1.18
Financial Health
Debt-to-Equity-2.1%
Free Cash Flow Yield-70.39%
Growth & Risk
Beta (5Y)1.47
Sharpe Ratio-0.46